Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026
Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026
Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Company Drug

NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer

Fineline Cube Feb 10, 2025

The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...

Policy / Regulatory

Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures

Fineline Cube Feb 10, 2025

An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...

Company Drug

Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment

Fineline Cube Feb 10, 2025

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

NMPA Seeks Public Feedback on Export Drug Manufacturing Rules

Fineline Cube Feb 10, 2025

An In – Depth Look at the New Draft Proposal for the Administration and Management...

Company Deals

VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally

Fineline Cube Feb 10, 2025

China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...

Policy / Regulatory

China’s Drug Procurement Under Scrutiny: Addressing Quality Concerns and Policy Reforms

Fineline Cube Feb 10, 2025

An In – Depth Exploration of the Recent Survey on Bulk Drug Procurement in China...

Policy / Regulatory

In-Depth Analysis of NHSA’s DRG/DIP Payment Reforms: A Path to Streamlined Healthcare Management

Fineline Cube Feb 10, 2025

Comprehensive Overhaul of Payment SystemsThe National Healthcare Security Administration (NHSA) has unveiled a series of...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study

Fineline Cube Feb 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment

Fineline Cube Feb 8, 2025

China-based Nuance Pharma announced that it has received regulatory approval in Macau for its Ohtuvayre...

Company

Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF

Fineline Cube Feb 8, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that the US Food and Drug Administration...

Company Drug

Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment

Fineline Cube Feb 8, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Company Drug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Fineline Cube Feb 8, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...

Company Drug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

Fineline Cube Feb 8, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...

Company

RemeGen’s Executive Director He Ruyi Resigns for Career Development

Fineline Cube Feb 8, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study

Fineline Cube Feb 8, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Feb 8, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...

Company Drug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Fineline Cube Feb 8, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Posts pagination

1 … 206 207 208 … 656

Recent updates

  • Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
  • Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
  • Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
  • Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
  • Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.